Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK

International Journal of Cancer

Volumn 115, Issue 2, 2005, Pages 276-283

  Lo, Yen Li ^a,b   Yu, Jyh Cherng ^c   Chen, Shou Tung ^d   Yang, Hsin Chou ^b   Fann, Cathy S J ^b   Mau, Yi Chien ^b   Shen, Chen Yang ^b,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e ACADEMIA SINICA   (Taiwan)

Author keywords

Aurora A STK15 BTAK; Breast cancer; Mitotic checkpoint; Molecular epidemiology; Polymorphism

Indexed keywords

ESTROGEN;

ALLELE; ANEUPLOIDY; ARTICLE; AURORA A GENE; BREAST CANCER; BREAST CARCINOGENESIS; BTAK GENE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL PROLIFERATION; CENTROSOME; CHROMOSOME NUMBER; CONTROLLED STUDY; FEMALE; GENE; GENE DUPLICATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MENARCHE; MITOSIS RATE; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STK15 GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CENTROSOME; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GENOTYPE; HAPLOTYPES; HUMANS; MENARCHE; MITOSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 17844381081     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20855     Document Type: Article

References (60)

1. Loeb LA. A mutator phenotype in cancer. Cancer Res 2001;61: 3230-9.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
3. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177-84.
4. Mendelin J, Grayson M, Wallis T, Visscher DW. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Invest 1999;79:387-93.
5. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12:82-8.
6. Draviam VM, Xie S, Sorger PK. Chromosome segregation and genomic stability, Curr Opin Genet Dev 2004;14:120-5.
7. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nature Rev Cancer 2001;1:109-17.
8. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci USA 1998:95:2950-5.
9. Pihan GA, Purohit A. Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998;58:3974-85.
10. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nature Rev Cancer 2002;2:1-11.
11. Bischoff JR, Plowman GD. The Aurora/Ip11p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-9.
12. Zhou H, Kuang J, Zhong L, Kuo WL, Gray J, Sahin A, Brinkley B, Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
13. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
14. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
15. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-71.
16. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003;63:1398-404.
17. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000;27:135-45.
18. Yang PS, Yang TL, Liu CL, Wu CW, Shen CY. A case-control study of breast cancer in Taiwan-a low-incidence area. Br J Cancer 1997;75:752-6.
19. Lo YL, Yu JC, Huang CS, Tseng SL, Chang TM, Chang KJ, Wu CW, Shen CY. Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int J Cancer 1998;79:580-7.
20. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5.
21. Yang TL, Su YR, Huang CS, Yu JC, Lo YL, Wu PE, Shen CY. High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity. Genes Chromosomes Cancer 2004;41:250-6.
22. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
23. Lou MA, Tseng SL, Chang SF, Yue CT, Chang BL, Chou CH, Yang SL, The BH, Wu CW, Shen CY. Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. Br J Cancer 1997;75:746-51.
24. Lung JC, Chu JS, Yu JC, Yue CT, Lo YL, Shen CY, Wu CW. Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Genes Chromosomes Cancer 2002;34:276-84.
25. Huang CS, Chern HD, Shen CY, Hsu SM, Chang KJ. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int J Cancer 1999;82:175-9.
26. Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, Wu CY, Chen ST, Wu HS, Wu PE, Shen CY. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res 2003; 63: 2440-6.
27. Cheng TC, Chen ST, Yu JC, Fu YP, Huang CS, Cheng CW, Wu PE, Shen CY. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer 2005;113:345-53.
28. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001;46:471-7.
29. Sellers TA. Genetic ancestry and molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2004;13:499-500.
30. Kleinbaum DG, Kupper LL, Morgenstern KH. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
31. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
32. Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 1964;50:757-82.
33. Zhao JH, Sham PC. Faster haplotype frequency estimation using unrelated subjects. Hum Hered 2002;53:36-41.
34. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. Hum Hered 2000;50:133-9.
35. Khoury M. Genetic epidemiology. In: Rothman KJ, Greenland S, eds. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven, 1998.609-21.
36. Botto LD, Khoury MJ. Facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 2001;153:1016-20.
37. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. Boston: PWS-KENT, 1998.
38. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BAJ, Nagase H, Burn J, Ball S, Almeida M, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34:403-12.
39. Miao X, Sun T, Wang Y, Zhang X, Tan W, Lin D. Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res 2004;64:2680-3.
40. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
41. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2:5-73.
42. Ding SL, Sheu LF, Yu JC, Yang TL, Chen BF, Leu FJ, Shen CY. Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumor grade. Br J Cancer 2004;90:1995-2001.
43. Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, Shen CY. Breast cancer risk and the DNA double-strand break end-joining capacity of non-homologous end-joining genes are affected by BRCA1. Cancer Res 2004;64:5013-9.
44. Vogelstein B, Kinzler KW. The genetic basis of human cancer, 2nd ed. London: McGraw-Hill, 2002.
45. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
46. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392:300-3.
47. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004;36:55-62.
48. Kirk BW, Feinsod M, Favis R, Kliman RM, Barany F. Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res 2002;30:3295-311.
49. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 2001;20:3814-23.
50. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562-74.
51. Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W. Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2003;12:853-9.
52. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Eastern DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;3:33-6.
53. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003;4:251-6.
54. Sun T, Miao X, Wang J, Tan W, Zhou Y, Yu C, Lin D. Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 2004;25:2225-30.
55. Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Kimura MT, Nagase H. STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 2004;25:2149-53.
56. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Hogdall E, Shah MN, Luben RN, Easton DF, Jacobs IJ, Ponder BA, et al. STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1589-94.
57. Helland A, Borresen-Dale AL. p53 polymorphism and cervical cancer. Lancet 1999;345:1561-2.
58. 2 to M transition. J Biol Chem 2004;279:19643-8.
59. Marx J. Debate surges over the origins of genomic defects in cancer. Science 2002;297:544-6.
60. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-27.